Resumen
There is considerable overlap in age-related risk factors for influenza and COVID-19. We explored the impact of the pandemic on anticipated influenza and COVID-19 vaccination behaviour in the 2020/2021 season. In May 2020, we conducted online surveys of Canadian adults 50 years and older via a market research panel platform, as part of a series of annual surveys to understand experiences with influenza. Given the current pandemic, respondents were also asked about COVID- 19‘s impact on their vaccination decision-making for the 2020/2021 season. Of 1001 respondents aged 50-64 years, 470 (47.0%) originally intended on receiving the influenza vaccine and still planned to do so, while 200 (20%) respondents who had planned to abstain now reported willingness to receive the vaccine due to COVID-19. In the 65+ age group, 2525 (72.1%) reported that they had planned to be vaccinated and that COVID-19 had not changed their mind, while 285 individuals (8.1%) reported that they had initially planned to forgo the vaccine but now intended to receive it. Reasons for this change included COVID-19‘s demonstration of the devastating potential of viruses; and to protect against influenza, and decrease vulnerability to COVID-19. If the COVID-19 vaccine was available, 69.1% of 50-64 year olds and 79.5% of those 65 years and older reported they would opt to receive it. The COVID-19 pandemic has been a sobering demonstration of the dangers of infectious disease, and the value of vaccines, with implications for influenza and COVID-19 immunization programs.
| Idioma original | English |
|---|---|
| Número de artículo | 346 |
| Publicación | Vaccines |
| Volumen | 9 |
| N.º | 4 |
| DOI | |
| Estado | Published - abr. 2021 |
Nota bibliográfica
Funding Information:Funding: This research was funded by Sanofi Pasteur. The authors of the study had full control of study design, data collection and analysis, decision to publish, and preparation of the manuscript.
Funding Information:
Conflicts of Interest: Waite reports grants from Sanofi Pasteur during the conduct of the study, and personal fees from Sanofi Pasteur outside the submitted work. Pereira has previously provided consulting services to Sanofi Pasteur, outside of the submitted work. Houle reports grants from Sanofi Pasteur during the conduct of the study, and grants and personal fees from GSK, personal fees from Astra Zeneca, grants from Sanofi and Merck outside of the submitted work. Andrew reports grants from Sanofi during the conduct of the study, and grants from Sanofi, GSK, Pfizer and the Canadian Frailty Network, personal fees from Immunovaccine Technologies, Sanofi, Pfizer and Seqirus and grants from the Canadian Institutes of Health Research and the Public Health Agency of Canada, outside of the submitted work.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
ASJC Scopus Subject Areas
- Immunology
- Pharmacology
- Drug Discovery
- Infectious Diseases
- Pharmacology (medical)
PubMed: MeSH publication types
- Journal Article
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
